Search Results - "Cummons, Terri A."
-
1
The persistence of a long-term negative affective state following the induction of either acute or chronic pain
Published in Pain (Amsterdam) (01-12-2008)“…Clinically, pain is a complex phenomenon consisting of both sensory and affective aberrations that can persist indefinitely. Pre-clinically, several animal…”
Get full text
Journal Article -
2
Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity
Published in The Journal of pharmacology and experimental therapeutics (01-06-2005)“…Perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] is a selective, competitive N-methyl-D-aspartate (NMDA)…”
Get more information
Journal Article -
3
An estrogen receptor-β agonist is active in models of inflammatory and chemical-induced pain
Published in European journal of pharmacology (28-12-2006)“…ERB-041 (2-(3-Fluoro-4-hydroxyphenyl)-7-vinyl-1,3 benzoxazol-5-ol) is a selective estrogen receptor-β agonist with activity in rodent models of rheumatoid…”
Get full text
Journal Article -
4
Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in vitro and in vivo models of chronic pain
Published in The Journal of pharmacology and experimental therapeutics (01-09-2007)“…Here, we have investigated the in vitro pharmacology of a muscarinic agonist, (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane…”
Get more information
Journal Article -
5
Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models
Published in Brain research (12-10-2009)“…Abstract Validation of gait analysis has the potential to bridge the gap between data from animal pain models and clinical observations. The goal of these…”
Get full text
Journal Article -
6
Prodrugs of Perzinfotel with Improved Oral Bioavailability
Published in Journal of medicinal chemistry (12-02-2009)“…Previous studies with perzinfotel (1), a potent, selective, competitive NMDA receptor antagonist, showed it to be efficacious in inflammatory and neuropathic…”
Get full text
Journal Article